MovDisordV3, PascalFrancis, Corpus, bibRecord, 002464

Long-term outcome of quetiapine use for psychosis among parkinsonian patients

Identifieur interne : 002464 ( PascalFrancis/Corpus ); précédent : 002463; suivant : 002465

Long-term outcome of quetiapine use for psychosis among parkinsonian patients

Auteurs : Hubert H. Fernandez ; Martha E. Trieschmann ; Monica A. Burke ; Carol Jacques ; Joseph H. Friedman

Source :

Movement disorders [ 0885-3185 ] ; 2003.

RBID : Pascal:03-0380057

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Psychose, Quétiapine, Neuroleptique, Antipsychotique, Dose faible, Chimiothérapie, Efficacité traitement, Personne âgée, Long terme, Etude cohorte.

English descriptors

KwdEn :
- Antipsychotic, Chemotherapy, Cohort study, Elderly, Long term, Low dose, Neuroleptic, Parkinson disease, Psychosis, Quetiapine, Treatment efficiency.

Abstract

To evaluate the long-term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)-motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L-dopa) dose of 415 mg/d. Seventy-eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty-seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non-responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95%. CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07).

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 18`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Long-term outcome of quetiapine use for psychosis among parkinsonian patients`
A11	`01`	`1`		`@1 FERNANDEZ (Hubert H.)`
A11	`02`	`1`		`@1 TRIESCHMANN (Martha E.)`
A11	`03`	`1`		`@1 BURKE (Monica A.)`
A11	`04`	`1`		`@1 JACQUES (Carol)`
A11	`05`	`1`		`@1 FRIEDMAN (Joseph H.)`
A14	`01`			`@1 Department of Clinical Neurosciences, Brown University School of Medicine @2 Providence, Rhode Island @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut.`
A20				`@1 510-514`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000118200090050`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 39 ref.`
A47	`01`	`1`		`@0 03-0380057`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 To evaluate the long-term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)-motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L-dopa) dose of 415 mg/d. Seventy-eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty-seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non-responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95%. CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07).
C02	`01`	`X`		`@0 002B02B03`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Psychose @5 04`
C03	`02`	`X`	`ENG`	`@0 Psychosis @5 04`
C03	`02`	`X`	`SPA`	`@0 Psicosis @5 04`
C03	`03`	`X`	`FRE`	`@0 Quétiapine @2 NK @2 FR @5 07`
C03	`03`	`X`	`ENG`	`@0 Quetiapine @2 NK @2 FR @5 07`
C03	`03`	`X`	`SPA`	`@0 Quetiapina @2 NK @2 FR @5 07`
C03	`04`	`X`	`FRE`	`@0 Neuroleptique @5 08`
C03	`04`	`X`	`ENG`	`@0 Neuroleptic @5 08`
C03	`04`	`X`	`SPA`	`@0 Neuroléptico @5 08`
C03	`05`	`X`	`FRE`	`@0 Antipsychotique @5 09`
C03	`05`	`X`	`ENG`	`@0 Antipsychotic @5 09`
C03	`05`	`X`	`SPA`	`@0 Antipsicótico @5 09`
C03	`06`	`X`	`FRE`	`@0 Dose faible @5 10`
C03	`06`	`X`	`ENG`	`@0 Low dose @5 10`
C03	`06`	`X`	`SPA`	`@0 Dosis débil @5 10`
C03	`07`	`X`	`FRE`	`@0 Chimiothérapie @5 16`
C03	`07`	`X`	`ENG`	`@0 Chemotherapy @5 16`
C03	`07`	`X`	`SPA`	`@0 Quimioterapia @5 16`
C03	`08`	`X`	`FRE`	`@0 Efficacité traitement @5 17`
C03	`08`	`X`	`ENG`	`@0 Treatment efficiency @5 17`
C03	`08`	`X`	`SPA`	`@0 Eficacia tratamiento @5 17`
C03	`09`	`X`	`FRE`	`@0 Personne âgée @5 20`
C03	`09`	`X`	`ENG`	`@0 Elderly @5 20`
C03	`09`	`X`	`SPA`	`@0 Anciano @5 20`
C03	`10`	`X`	`FRE`	`@0 Long terme @5 23`
C03	`10`	`X`	`ENG`	`@0 Long term @5 23`
C03	`10`	`X`	`SPA`	`@0 Largo plazo @5 23`
C03	`11`	`X`	`FRE`	`@0 Etude cohorte @5 24`
C03	`11`	`X`	`ENG`	`@0 Cohort study @5 24`
C03	`11`	`X`	`SPA`	`@0 Estudio cohorte @5 24`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`07`	`X`	`FRE`	`@0 Posologie @5 61`
C07	`07`	`X`	`ENG`	`@0 Posology @5 61`
C07	`07`	`X`	`SPA`	`@0 Posología @5 61`
N21				`@1 265`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 03-0380057 INIST
ET :	Long-term outcome of quetiapine use for psychosis among parkinsonian patients
AU :	FERNANDEZ (Hubert H.); TRIESCHMANN (Martha E.); BURKE (Monica A.); JACQUES (Carol); FRIEDMAN (Joseph H.)
AF :	Department of Clinical Neurosciences, Brown University School of Medicine/Providence, Rhode Island/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. 5; Pp. 510-514; Bibl. 39 ref.
LA :	Anglais
EA :	To evaluate the long-term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)-motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L-dopa) dose of 415 mg/d. Seventy-eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty-seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non-responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95%. CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07).
CC :	002B02B03; 002B17G
FD :	Parkinson maladie; Psychose; Quétiapine; Neuroleptique; Antipsychotique; Dose faible; Chimiothérapie; Efficacité traitement; Personne âgée; Long terme; Etude cohorte
FG :	Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Posologie
ED :	Parkinson disease; Psychosis; Quetiapine; Neuroleptic; Antipsychotic; Low dose; Chemotherapy; Treatment efficiency; Elderly; Long term; Cohort study
EG :	Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Posology
SD :	Parkinson enfermedad; Psicosis; Quetiapina; Neuroléptico; Antipsicótico; Dosis débil; Quimioterapia; Eficacia tratamiento; Anciano; Largo plazo; Estudio cohorte
LO :	INIST-20953.354000118200090050
ID :	03-0380057

Links to Exploration step

Pascal:03-0380057

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-term outcome of quetiapine use for psychosis among parkinsonian patients</title>
<author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E." last="Trieschmann">Martha E. Trieschmann</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Burke, Monica A" sort="Burke, Monica A" uniqKey="Burke M" first="Monica A." last="Burke">Monica A. Burke</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jacques, Carol" sort="Jacques, Carol" uniqKey="Jacques C" first="Carol" last="Jacques">Carol Jacques</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0380057</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0380057 INIST</idno>
<idno type="RBID">Pascal:03-0380057</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002464</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-term outcome of quetiapine use for psychosis among parkinsonian patients</title>
<author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E." last="Trieschmann">Martha E. Trieschmann</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Burke, Monica A" sort="Burke, Monica A" uniqKey="Burke M" first="Monica A." last="Burke">Monica A. Burke</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jacques, Carol" sort="Jacques, Carol" uniqKey="Jacques C" first="Carol" last="Jacques">Carol Jacques</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic</term>
<term>Chemotherapy</term>
<term>Cohort study</term>
<term>Elderly</term>
<term>Long term</term>
<term>Low dose</term>
<term>Neuroleptic</term>
<term>Parkinson disease</term>
<term>Psychosis</term>
<term>Quetiapine</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Psychose</term>
<term>Quétiapine</term>
<term>Neuroleptique</term>
<term>Antipsychotique</term>
<term>Dose faible</term>
<term>Chimiothérapie</term>
<term>Efficacité traitement</term>
<term>Personne âgée</term>
<term>Long terme</term>
<term>Etude cohorte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To evaluate the long-term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)-motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L-dopa) dose of 415 mg/d. Seventy-eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty-seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non-responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95%. CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07).</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Long-term outcome of quetiapine use for psychosis among parkinsonian patients</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FERNANDEZ (Hubert H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TRIESCHMANN (Martha E.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BURKE (Monica A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>JACQUES (Carol)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FRIEDMAN (Joseph H.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>510-514</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000118200090050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>39 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0380057</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>To evaluate the long-term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)-motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L-dopa) dose of 415 mg/d. Seventy-eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty-seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non-responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95%. CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07).</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B03</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Psychose</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Psychosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Psicosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Quétiapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Quetiapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quetiapina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Neuroleptique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Neuroleptic</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Neuroléptico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Antipsychotique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Antipsychotic</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Antipsicótico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Dose faible</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Low dose</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Dosis débil</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Efficacité traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment efficiency</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Personne âgée</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Elderly</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Anciano</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Long terme</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Long term</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Etude cohorte</s0>
<s5>24</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Cohort study</s0>
<s5>24</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Estudio cohorte</s0>
<s5>24</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Posologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Posology</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Posología</s0>
<s5>61</s5>
</fC07>
<fN21><s1>265</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 03-0380057 INIST</NO>
<ET>Long-term outcome of quetiapine use for psychosis among parkinsonian patients</ET>
<AU>FERNANDEZ (Hubert H.); TRIESCHMANN (Martha E.); BURKE (Monica A.); JACQUES (Carol); FRIEDMAN (Joseph H.)</AU>
<AF>Department of Clinical Neurosciences, Brown University School of Medicine/Providence, Rhode Island/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. 5; Pp. 510-514; Bibl. 39 ref.</SO>
<LA>Anglais</LA>
<EA>To evaluate the long-term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)-motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L-dopa) dose of 415 mg/d. Seventy-eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty-seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non-responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95%. CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07).</EA>
<CC>002B02B03; 002B17G</CC>
<FD>Parkinson maladie; Psychose; Quétiapine; Neuroleptique; Antipsychotique; Dose faible; Chimiothérapie; Efficacité traitement; Personne âgée; Long terme; Etude cohorte</FD>
<FG>Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Posologie</FG>
<ED>Parkinson disease; Psychosis; Quetiapine; Neuroleptic; Antipsychotic; Low dose; Chemotherapy; Treatment efficiency; Elderly; Long term; Cohort study</ED>
<EG>Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Posology</EG>
<SD>Parkinson enfermedad; Psicosis; Quetiapina; Neuroléptico; Antipsicótico; Dosis débil; Quimioterapia; Eficacia tratamiento; Anciano; Largo plazo; Estudio cohorte</SD>
<LO>INIST-20953.354000118200090050</LO>
<ID>03-0380057</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002464 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002464 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:03-0380057
   |texte=   Long-term outcome of quetiapine use for psychosis among parkinsonian patients
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Long-term outcome of quetiapine use for psychosis among parkinsonian patients

Long-term outcome of quetiapine use for psychosis among parkinsonian patients

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri